Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses

Journal of Radiation Oncology - Tập 4 - Trang 65-70 - 2014
Nisha R. Patel1, Rachelle Lanciano2,1, Karna Sura1, Jun Yang2,1, John Lamond2,1, Jing Feng2, Michael Good2, Ed J. Gracely1, Lydia Komarnicky1, Luther Brady2,1
1Department of Radiation Oncology, Drexel University College of Medicine, Philadelphia, USA
2Department of Radiation Oncology, Delaware County Memorial Hospital, Philadelphia CyberKnife Center, Havertown, USA

Tóm tắt

Few studies have evaluated re-irradiation of lung cancer recurrences with stereotactic body radiotherapy (SBRT). This study evaluates outcomes with SBRT re-irradiation for recurrent lung cancer. Two hundred and seventy-eight patients treated with SBRT for lung cancer were retrospectively reviewed. Of those, 26 patients with 29 tumors were re-irradiated with SBRT. Ninety percent of tumors received prior external beam irradiation and 10 % received prior SBRT. Previous median radiation dose was 61.2 Gy with a median 8-month interval from previous radiation. The median re-irradiation SBRT dose was 30 Gy (48 Gy10 biological effective dose (BED)). Endpoints evaluated included local control, overall survival, and progression-free survival. Twenty-five of 29 tumors were evaluable for local control, with 27 tumors (93 %) considered in-field recurrences. In-field crude local control rate was 80 % (20/25) with 1 and 2-year actuarial rates of 78.6 and 65.5 %, respectively. One and 2-year actuarial survival rates were 52.3 and 37.0 %, respectively. One and 2-year actuarial progression-free survival rates were 56.7 and 37.0 %, respectively. Fifty-five percent of patients reported acute/chronic grades 1 and 2 toxicities. No grade 3 or higher toxicities were reported. Patients with recurrent lung cancer have limited options. SBRT re-irradiation is tolerable even after a median 61.2 Gy to the re-irradiation site. The lower BED used provided acceptable progression-free survival with low toxicity. Given the poor prognosis with current treatment options, new paradigms for re-treatment should include SBRT-re-irradiation as an adjunct to systemic therapy for in-field lung cancer recurrence.

Tài liệu tham khảo

Curran WJ Jr, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460 Le Chevalier T, Arriagada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell1lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423 Sause W, Scott C, Taylor S et al (1995) Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198–205 Dillman S, Herdon J, Seagren S et al (1996) Improved survival in stage III non-small cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 Trial. J Natl Cancer Inst 88:1210–1215 Schaake-Koning C, Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell cancer. NEJM 326:524–530 Blackstock AW, Govindan R (2007) Definitive chemoradiation for the treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 25:4146–4152 Tada T, Fukuda H, Matsui K et al (2005) Non-small-cell lung cancer: re-irradiation for loco-regional relapse previously treated with radiation therapy. Int J Clin Oncol 10:247–250 Okamoto Y, Murakami M, Yoden E et al (2002) Re-irradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys 52:390–396 Green N, Melbye RW (1982) Lung cancer: retreatment of local recurrence after definitive irradiation. Cancer 49:865–868 Montebello JF, Aron BS, Manatunga AK et al (1993) The re-irradiation of recurrent bronchogenic carcinoma with external beam radiation. Am J Clin Oncol 16:482–488 Kramer GW, Gans S, Ullmann E et al (2004) Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int J Radiat Oncol Biol Phys 58:1388–1393 Jeremic B, Videtic GM (2011) Chest re-irradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys 80:969–977 Noble J, Ellis PM, Mackay JA et al (2006) Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 1:1042–1058 Kelly P, Balter PA, Rebueno N et al (2010) Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 78:1387–1393 Peulen H, Karlsson K, Lindberg K et al (2011) Toxicity after re-irradiation of pulmonary tumours with stereotactic body radiotherapy. Radiat Oncol 101:260–266 Seung S, Solhjem M et al (2011) Salvage for previously irradiated lung cancer. J Cancer Ther 2:190–195 Trakul N, Harris JP, MPhil BS et al (2012) Stereotactic ablative radiotherapy for re-irradiation of locally recurrent tumors. J Thorac Oncol 9:1462–1465 Trovo M, Minatel E, Durofil RT et al (2014) Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88:1115–1119 Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076 Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for Stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 101:1623–1631 Fowler JF, Tomé WA, Fenwick JD, Mehta MP (2004) A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 60:1241–1256 Mehta N, King CR, Agazaryan N et al (2012) Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol 2:288–295 Dunlap NE, Yang W, McIntosh A et al (2012) Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84:1072–1077 Nieder C, Grosu AL, Andratschkelaus NH et al (2005) Proposal of human spinal cord re-irradiation dose based upon collection of data from 40 patients. Int J Radiat Oncol Biol Phys 6:851–855 Sahgal A, Ma L, Weinberg V et al (2012) Re-irradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 82:107–116 Liu H, Zhang X, Vinogradskiy Y et al (2012) Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys 84:1017–1023